|Bid||1.8700 x 800|
|Ask||1.9000 x 800|
|Day's Range||1.8300 - 1.9200|
|52 Week Range||1.8150 - 5.9700|
|Beta (5Y Monthly)||1.25|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Atyr Pharma (LIFE) delivered earnings and revenue surprises of 45.83% and 592.40%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Atyr Pharma (LIFE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).